Data shows that in 2022, 2.5 billion adults were overweight, including over 890 million adults who were living with obesity. In the UK, it’s estimated that around 1 in every 4 adults are living with obesity.
The World Health Organisation defines people who are overweight to have a BMI greater than or equal to 25 and people who are obese has a BMI greater than or equal to 30.
Both weight loss pills and injections can accelerate weight loss for people who are overweight or obese when used alongside a weight management program that includes realistic goals, healthy lifestyle changes and regular monitoring. In this article we discuss Mounjaro (Tirzepatide), a new weight loss treatment and the first injectable drug to target two hormones.
Mounjaro is a drug used for the management of type 2 diabetes and weight loss. It is a dual-action prescription medication which mimics both GLP-1 and GIP receptors responsible for glucose metabolism and appetite regulation. This makes it a pioneering treatment compared to other diabetes medications, which typically only target GLP-1 receptors.
It is designed to promote weight loss in obese adults with a BMI of 30kg/m² or more, as well as overweight people with a BMI between 27-30kg/m² who also have related health issues such as high blood pressure or cholesterol, heart problems or prediabetes.
Mounjaro works by targeting and copying principal hormones responsible for your appetite and glucose.
This helps to slow down the time it takes for food to empty out of your stomach, leaving you feeling less hungry and fuller for longer. It also improves how well your body processes food and converts it into energy. It is injected once a week with the single-use Mounjaro KiwkPen.
Mounjaro is available in six different doses. The starting dose is 2.5mg and this increases to the maximum dose of 15mg.
You always start with a dose of 2.5mg, once a week for four weeks. This gives your body time to get used to the drug and lowers your risk of side effects.
After four weeks, your dose may increase to 5mg once a week if needed.
The dose may then be increased in a minimum of 4-week intervals up to the maximum dose of 15mg once weekly, if recommended by your doctor.
If the current dose you are taking is managing your hunger and cravings, you should not increase the dosage of your mounjaro injection.
We recommend reading our guide on “How to Use Mounjaro” which provides detailed information on dosages, administering injections, and troubleshooting common issues such as pen malfunctions.
To deliver dose of | 2.5mg dose contained in each click 0.042mg | 5mg dose contained in each click 0.083mg | 7.5mg dose contained in each click 0.125mg | 10mg dose contained in each click 0.166mg | 12.5mg dose contained in each click 0.208mg | 15mg dose contained in each click 0.25mg |
---|---|---|---|---|---|---|
2.5 mg | 60 | 30 | 20 | 15 | 12 | 10 |
5 mg | – | 60 | 40 | 30 | 24 | 20 |
7.5 mg | – | – | 60 | 45 | 36 | 30 |
10 mg | – | – | – | 60 | 48 | 40 |
12.5 mg | – | – | – | – | 60 | 50 |
15mg | – | – | – | – | – | 60 |
The response to weight loss medications varies from person to person. Although lower doses are effective for reducing appetite and minimising gastrointestinal side effects, it may not be sufficient for substantial weight loss in some cases. Clinical studies have shown that Mounjaro improves fat metabolism and reduces body fat, therefore increasing the dose when recommended and tolerated can help to boost the fat-burning process.
It’s possible for some people to see moderate weight loss within the first few weeks of using Mounjaro. However, it can take around 3- 6 months for you to see significant changes to your weight as the dosage gradually increases. It’s important to remember that your weight loss journey takes time and there is no overnight remedy. This medication works best when it is used in conjunction with a weight management plan including a healthy well-balanced diet and exercise routine.
Not everyone will have side effects. If you do experience them, the most common typically lasts between and few days and a couple of weeks and they tend to go away on their own. This usually happens as your body gets used to the medication. Side effects affecting the gut such as vomiting, diarrhoea, nausea and stomach pain are the most commonly reported. The length and severity can vary due to your own tolerance, dosage and how long you have been using Mounjaro.
The length of time the drug stays in your system can depend on how your kidney and liver function, as well as your age and general health. It can take around 5 days for half of the drug to leave your body and around 20 to 25 days for most of Mounjaro to be removed after your last dose. It can however take longer than this for some people.
Mounjaro is considered safe and has been approved to treat adults with type 2 diabetes and for weight management by The Medicines and Healthcare products Regulatory Agency (MHRA).
The approval was based on evidence around efficacy and safety of Tirzepatide when used for weight management in overweight and obese adults with and without diabetes. The trials found that overweight or obese adults treated with Tirzepatide saw significant reductions in body weight compared to placebo, regardless of gender, age, race, ethnicity, body mass index and glycaemic (status).
The MHRA keeps the safety and effectiveness of Mounjaro under close review and you should always buy mounjaro online from a pharmacy registered with the General Pharmaceutical Council (GPhC) because they are regulated and licensed to sell it.
Both Mounjaro and Wegovy are weight loss injections effective in helping manage body weight and type 2 diabetes, however there are some key differences:
Both Mounjaro and Ozempic regulate blood sugar and slow down digestion, leaving you feeling full and reducing your appetite. The way this is achieved differs between the two:
GOV.UK (2023). Mounjaro (tirzepatide) for weight management and weight loss. Retrieved 24th October 2024, from: https://www.gov.uk/government/news/mhra-authorises-diabetes-drug-mounjaro-tirzepatide-for-weight-management-and-weight-loss
GOV.UK (2024). Four-dose Mounjaro “KwikPen” approved by MHRA for diabetes and weight management. Retrieved 24th October 2024, from: https://www.gov.uk/government/news/four-dose-mounjaro-kwikpen-approved-by-mhra-for-diabetes-and-weight-management
W.H.O (2024). Obesity and Overweight. Retrieved 24th October 2024, from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
National Library of Medicine (2024). The Body weight Reducing Effects of Tirzepatide. Retrieved 24th October 2024, from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10861994/
Whilst all of our content is written and reviewed by healthcare professionals, it is not intended to be substituted for or used as medical advice. If you have any questions or concerns about your health, please speak to your doctor.